These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19139015)

  • 1. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.
    Czerninski R; Amornphimoltham P; Patel V; Molinolo AA; Gutkind JS
    Cancer Prev Res (Phila); 2009 Jan; 2(1):27-36. PubMed ID: 19139015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
    Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
    Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
    Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model.
    Raimondi AR; Molinolo A; Gutkind JS
    Cancer Res; 2009 May; 69(10):4159-66. PubMed ID: 19435901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors.
    Granville CA; Warfel N; Tsurutani J; Hollander MC; Robertson M; Fox SD; Veenstra TD; Issaq HJ; Linnoila RI; Dennis PA
    Clin Cancer Res; 2007 Apr; 13(7):2281-9. PubMed ID: 17404113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN deficiency contributes to the development and progression of head and neck cancer.
    Squarize CH; Castilho RM; Abrahao AC; Molinolo A; Lingen MW; Gutkind JS
    Neoplasia; 2013 May; 15(5):461-71. PubMed ID: 23633918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin.
    Patel H; Younis RH; Ord RA; Basile JR; Schneider A
    J Oral Pathol Med; 2013 Mar; 42(3):250-6. PubMed ID: 22861817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.
    Molinolo AA; Hewitt SM; Amornphimoltham P; Keelawat S; Rangdaeng S; Meneses García A; Raimondi AR; Jufe R; Itoiz M; Gao Y; Saranath D; Kaleebi GS; Yoo GH; Leak L; Myers EM; Shintani S; Wong D; Massey HD; Yeudall WA; Lonardo F; Ensley J; Gutkind JS
    Clin Cancer Res; 2007 Sep; 13(17):4964-73. PubMed ID: 17785546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral-specific ablation of Klf4 disrupts epithelial terminal differentiation and increases premalignant lesions and carcinomas upon chemical carcinogenesis.
    Paparella ML; Abrigo M; Bal de Kier Joffe E; Raimondi AR
    J Oral Pathol Med; 2015 Nov; 44(10):801-9. PubMed ID: 25605610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
    Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
    Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
    Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
    Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
    Ekshyyan O; Mills GM; Lian T; Amirghahari N; Rong X; Lowery-Nordberg M; Abreo F; Veillon DM; Caldito G; Speicher L; Glass J; Nathan CO
    Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and clinical significance of the Kv3.4 potassium channel subunit in the development and progression of head and neck squamous cell carcinomas.
    Menéndez ST; Rodrigo JP; Allonca E; García-Carracedo D; Alvarez-Alija G; Casado-Zapico S; Fresno MF; Rodríguez C; Suárez C; García-Pedrero JM
    J Pathol; 2010 Aug; 221(4):402-10. PubMed ID: 20593490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
    Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions.
    Vitale-Cross L; Molinolo AA; Martin D; Younis RH; Maruyama T; Patel V; Chen W; Schneider A; Gutkind JS
    Cancer Prev Res (Phila); 2012 Apr; 5(4):562-73. PubMed ID: 22467081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.
    Patel V; Marsh CA; Dorsam RT; Mikelis CM; Masedunskas A; Amornphimoltham P; Nathan CA; Singh B; Weigert R; Molinolo AA; Gutkind JS
    Cancer Res; 2011 Nov; 71(22):7103-12. PubMed ID: 21975930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
    Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
    Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.